Evogene Ltd.

As of August 31, 2022, Evogene Ltd. is considered a risky investment due to its negative price-to-book value of -2.01, low EV to EBIT and EV to EBITDA ratios, a valuation ratio significantly below industry average, and a year-to-date return of -34.60%, which underperforms the S&P 500's 12.22%.

As of August 31, 2022, Evogene Ltd. is considered overvalued and "risky," with unfavorable valuation metrics including a negative Price to Book Value of -2.01, a P/E ratio of -0.6091, and a significant stock decline of 78.20% over the past year, despite a high ROCE of 174.95%.

As of February 21, 2025, Evogene Ltd. shows a mildly bearish trend, supported by bearish MACD, Bollinger Bands, moving averages, and KST indicators across multiple time frames, indicating weakness compared to the S&P 500.

As of March 2022, the management team of Evogene Ltd. includes Mr. Martin Gerstel (Chairman), Dr. Adrian Percy, Prof. Oded Shoseyov, Ms. Sarit Firon, Mr. Ziv Kop, and Dr. Kinneret Livnat Savitsky, comprising both directors and independent directors.

Evogene Ltd. is a biotechnology company focused on enhancing crop productivity, classified as a micro-cap with a market cap of $10.48 million. As of March 2025, it reported net sales of $2 million and a net loss of $3 million.

As of Jun 18, Evogene Ltd. has a market capitalization of 10.48 million, with net sales of 6.76 million and a net profit of -17.21 million over the latest four quarters. Shareholder's funds are at -1.45 million, and total assets amount to 39.86 million.